Are there differences between ceftolozane/tazobactam and ceftazidime/avibactam in treating patients with complicated abdominal infections? Evidence from clinical trials

References

• Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis. 2017;215(suppl_1):S28–S36.
   PubMed Web of Science ®Google Scholar
• Cultrera R, Libanore M, Barozzi A, et al. Ceftolozane/tazobactam and ceftazidime/avibactam for multidrug-resistant gram-negative infections in immunocompetent patients: a single-center retrospective study. Antibiotics (Basel). 2020;9(10):640.
   Web of Science ®Google Scholar
• Brink AJ. Epidemiology of carbapenem-resistant gram-negative infections globally. Curr Opin Infect Dis. 2019;32(6):609–616.
   PubMed Web of Science ®Google Scholar
• Baditoiu L, Axente C, Lungeanu D, et al. Intensive care antibiotic consumption and resistance patterns: a cross-correlation analysis. Ann Clin Microbiol Antimicrob. 2017;16(1):71.
   PubMedGoogle Scholar
• Clancy CJ, Potoski BA, Buehrle D, et al. Estimating the treatment of carbapenem-resistant Enterobacteriaceae infections in the United States using antibiotic prescription data. Open Forum Infect Dis. 2019;6(8):ofz344.
   PubMed Web of Science ®Google Scholar
• Zhong H, Zhao XY, Zhang ZL, et al. Evaluation of the efficacy and safety of ceftazidime/avibactam in the treatment of gram-negative bacterial infections: a systematic review and Meta-analysis. Int J Antimicrob Agents. 2018;52(4):443–450.
   PubMed Web of Science ®Google Scholar
• Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, Double-Blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis. 2015;60(10):1462–1471.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Nováček M, Kivistik Ü, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019;19(12):1299–1311.
   PubMed Web of Science ®Google Scholar
• Wagenlehner FM, Umeh O, Steenbergen J, et al. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015;385(9981):1949–1956.
   PubMed Web of Science ®Google Scholar
• Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, Double-Blind, phase 3 program. Clin Infect Dis. 2016;62(11):1380–1389.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364.
   PubMed Web of Science ®Google Scholar
• Goodlet KJ, Nicolau DP, Nailor MD. Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections. Ther Clin Risk Manage. 2016;12:1811–1826.
   PubMed Web of Science ®Google Scholar
• Vazquez JA, González Patzán LD, Stricklin D, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28(12):1921–1931.
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018;18(3):285–295.
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Lucasti C, Hershberger E, Miller B, et al. Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58(9):5350–5357.
   PubMed Web of Science ®Google Scholar
• Qin X, Tran BG, Kim MJ, et al. A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in asia. Int J Antimicrob Agents. 2017;49(5):579–588.
   PubMed Web of Science ®Google Scholar
• Lucasti C, Popescu I, Ramesh MK, et al. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J Antimicrob Chemother. 2013;68(5):1183–1192.
   PubMed Web of Science ®Google Scholar
• Carmeli Y, Armstrong J, Laud PJ, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16(6):661–673.
   PubMed Web of Science ®Google Scholar
• Che H, Wang J, Wang R, et al. Novel Beta-Lactam/Beta-Lactamase plus metronidazole vs carbapenem for complicated intra-abdominal infections: a Meta-analysis of randomized controlled trials. Open Forum Infect Dis. 2021;8(1):ofaa591.
   PubMed Web of Science ®Google Scholar
• Ferriols Lisart R, Pérez Pitarch A, Ferriols Lisart F, et al. An indirect comparison of efficacy and safety of ceftolozane/tazobactam, ceftazidime/avibactam versus meropenem in complicated intra-abdominal infections. Eur J Clin Pharm. 2018;20(2):63–71.
   Google Scholar
• Miller B, Popejoy MW, Hershberger E, et al. Characteristics and outcomes of complicated intra-abdominal infections involving Pseudomonas aeruginosa from a randomized, double-blind, phase 3 ceftolozane-tazobactam study. Antimicrob Agents Chemother. 2016;60(7):4387–4390.
   PubMed Web of Science ®Google Scholar